Marcela Del Rio

List of Publications by Year
in descending order

82 papers	3,314 citations	126858 33 h-index	155592 55 g-index
82 all docs	82 docs citations	82 times ranked	4003 citing authors

#	Article	IF	Citations
1	In vitro and In vivo Wound Healing-Promoting Activities of Human Cathelicidin LL-37. Journal of Investigative Dermatology, 2008, 128, 223-236.	0.3	284
2	Human embryonic stem-cell derivatives for full reconstruction of the pluristratified epidermis: a preclinical study. Lancet, The, 2009, 374, 1745-1753.	6.3	233
3	Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation, 2004, 77, 350-355.	0.5	168
4	Feeder Layer Cell Actions and Applications. Tissue Engineering - Part B: Reviews, 2015, 21, 345-353.	2.5	122
5	An In Vivo Model of Wound Healing in Genetically Modified Skin-Humanized Mice. Journal of Investigative Dermatology, 2004, 123, 1182-1191.	0.3	104
6	Kindler syndrome: Extension of FERMT1 mutational spectrum and natural history. Human Mutation, 2011, 32, 1204-1212.	1.1	102
7	Inhibition of Xenografted Human Melanoma Growth and Prevention of Metastasis Development by Dual Antiangiogenic/Antitumor Activities of Pigment Epithelium-Derived Factor. Cancer Research, 2004, 64, 5632-5642.	0.4	93
8	Clinical Results of an Autologous Engineered Skin. Cell and Tissue Banking, 2006, 7, 47-53.	0.5	93
9	A Preclinical Model for the Analysis of Genetically Modified Human SkinIn Vivo. Human Gene Therapy, 2002, 13, 959-968.	1.4	91
10	1α,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene, 2005, 24, 6533-6544.	2.6	91
11	Construction of Skin Equivalents for Gene Therapy of Recessive Dystrophic Epidermolysis Bullosa. Human Gene Therapy, 2004, 15, 921-933.	1.4	89
12	Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. FASEB Journal, 2001, 15, 2030-2032.	0.2	84
13	COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa. Molecular Therapy, 2017, 25, 2573-2584.	3.7	81
14	A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptinâ€targeted keratinocyte grafts. FASEB Journal, 2001, 15, 1529-1538.	0.2	68
15	Ex-vivo Gene Therapy Restores LEKTI Activity and Corrects the Architecture of Netherton Syndrome-derived Skin Grafts. Molecular Therapy, 2011, 19, 408-416.	3.7	65
16	Long-term Engraftment of Single Genetically Modified Human Epidermal Holoclones Enables Safety Pre-assessment of Cutaneous Gene Therapy. Molecular Therapy, 2007, 15, 1670-1676.	3.7	64
17	A cutaneous gene therapy approach to treat infection through keratinocyteâ€targeted overexpression of antimicrobial peptides. FASEB Journal, 2004, 18, 1931-1933.	0.2	62
18	Correction of Laminin-5 Deficiency in Human Epidermal Stem Cells by Transcriptionally Targeted Lentiviral Vectors. Molecular Therapy, 2008, 16, 1977-1985.	3.7	60

#	ARTICLE	IF	CITATIONS
19	Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight, 2019, 4, .	2.3	56
20	Topical Enzyme-Replacement Therapy Restores Transglutaminase 1 Activity and Corrects Architecture of Transglutaminase-1-Deficient Skin Grafts. American Journal of Human Genetics, 2013, 93, 620-630.	2.6	53
21	Targeted Gene Addition in Human Epithelial Stem Cells by Zinc-finger Nuclease-mediated Homologous Recombination. Molecular Therapy, 2013, 21, 1695-1704.	3.7	53
22	Revertant Mosaicism Due to a Second-Site Mutation in COL7A1 in a Patient with Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2010, 130, 2407-2411.	0.3	51
23	Development of a Bioengineered Skin-Humanized Mouse Model for Psoriasis. American Journal of Pathology, 2010, 177, 3112-3124.	1.9	51
24	Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes. Molecular Therapy - Nucleic Acids, 2016, 5, e307.	2.3	50
25	Acetylsalicylic Acid Inhibits Cell Proliferation by Involving Transforming Growth Factor-Î². Circulation, 2003, 107, 626-629.	1.6	49
26	Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosome-based novel therapies. Experimental Dermatology, 2014, 23, 199-201.	1.4	47
27	Assessment of Optimal Virus-Mediated Growth Factor Gene Delivery for Human Cutaneous Wound Healing Enhancement. Journal of Investigative Dermatology, 2008, 128, 1565-1575.	0.3	46
28	CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient. Molecular Therapy, 2018, 26, 2592-2603.	3.7	46
29	Preclinical Corrective Gene Transfer in Xeroderma Pigmentosum Human Skin Stem Cells. Molecular Therapy, 2012, 20, 798-807.	3.7	44
30	Induction of Scleroderma Fibrosis in Skinâ€Humanized Mice by Administration of Antiâˆ'Plateletâ€Derived Growth Factor Receptor Agonistic Autoantibodies. Arthritis and Rheumatology, 2016, 68, 2263-2273.	2.9	42
31	Mechanisms of Natural Gene Therapy in Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2014, 134, 2097-2104.	0.3	40
32	Differential Features between Chronic Skin Inflammatory Diseases Revealed in Skin-Humanized Psoriasis and Atopic Dermatitis Mouse Models. Journal of Investigative Dermatology, 2016, 136, 136-145.	0.3	37
33	Modeling normal and pathological processes through skin tissue engineering. Molecular Carcinogenesis, 2007, 46, 741-745.	1.3	34
34	The regenerative potential of fibroblasts in a new diabetesâ€induced delayed humanised wound healing model. Experimental Dermatology, 2013, 22, 195-201.	1.4	34
35	Development of Skin-Humanized Mouse Models of Pachyonychia Congenita. Journal of Investigative Dermatology, 2011, 131, 1053-1060.	0.3	32
36	Sustained phenotypic reversion of junctional epidermolysis bullosa dog keratinocytes: Establishment of an immunocompetent animal model for cutaneous gene therapy. Biochemical and Biophysical Research Communications, 2006, 339, 769-778.	1.0	30

#	Article	IF	Citations
37	In Vivo Assessment of Acute UVB Responses in Normal and Xeroderma Pigmentosum (XP-C) Skin-Humanized Mouse Models. American Journal of Pathology, 2010, 177, 865-872.	1.9	30
38	Aplasia cutis congenita with dystrophic epidermolysis bullosa: clinical and mutational study. British Journal of Dermatology, 2014, 170, 901-906.	1.4	30
39	Long-Term Faithful Recapitulation of Transglutaminase 1–Deficient Lamellar Ichthyosis in a Skin-Humanized Mouse Model, and Insights from Proteomic Studies. Journal of Investigative Dermatology, 2012, 132, 1918-1921.	0.3	27
40	Safe Selection of Genetically Manipulated Human Primary Keratinocytes with Very High Growth Potential Using CD24. Molecular Therapy, 2007, 15, 2186-2193.	3.7	25
41	A Humanized Mouse Model of HPV-Associated Pathology Driven by E7 Expression. PLoS ONE, 2012, 7, e41743.	1.1	23
42	Long-Term Survival of Type XVII Collagen Revertant Cells in an Animal Model of Revertant Cell Therapy. Journal of Investigative Dermatology, 2014, 134, 571-574.	0.3	23
43	Increased Susceptibility to Skin Carcinogenesis Associated with a Spontaneous Mouse Mutation in the Palmitoyl Transferase Zdhhc13 Gene. Journal of Investigative Dermatology, 2015, 135, 3133-3143.	0.3	22
44	Effects of photodynamic therapy on dermal fibroblasts from xeroderma pigmentosum and Gorlin-Goltz syndrome patients. Oncotarget, 2017, 8, 77385-77399.	0.8	22
45	A Comparison of Targeting Performance of Oncoretroviral Versus Lentiviral Vectors on Human Keratinocytes. Human Gene Therapy, 2003, 14, 1579-1585.	1.4	21
46	Keratinocyte cell lines derived from severe generalized recessive Epidermolysis Bullosa patients carrying a highly recurrent COL7A1 homozygous mutation: models to assess cell and gene therapies in vitro and in vivo. Experimental Dermatology, 2013, 22, 601-603.	1.4	20
47	Oxidative stress and mitochondrial dysfunction in Kindler syndrome. Orphanet Journal of Rare Diseases, 2014, 9, 211.	1.2	20
48	Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing. Molecular Therapy, 2021, 29, 2008-2018.	3.7	20
49	A prevalent mutation with founder effect in Spanish Recessive Dystrophic Epidermolysis Bullosa families. BMC Medical Genetics, 2010, 11, 139.	2.1	18
50	Targeted Overexpression of Leptin to Keratinocytes in Transgenic Mice Results in Lack of Skin Phenotype but Induction of Early Leptin Resistance. Endocrinology, 2005, 146, 4167-4176.	1.4	17
51	Epidermolysis Bullosa Simplex with Mottled Pigmentation: A Family Report and Review. Pediatric Dermatology, 2013, 30, e125-31.	0.5	17
52	Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients. Orphanet Journal of Rare Diseases, 2019, 14, 183.	1.2	16
53	Comparative study of elgodipine and nisoldipine on the contractile responses of various isolated blood vessels. European Journal of Pharmacology, 1995, 285, 115-122.	1.7	15
54	Tissue-Engineered Oral Mucosa for Mucosal Reconstruction in a Pediatric Patient with Hemifacial Microsomia and Ankyloglossia. Cleft Palate-Craniofacial Journal, 2014, 51, 246-251.	0.5	15

#	Article	IF	Citations
55	Estrategias terapéuticas innovadoras para la epidermólisis bullosa distrófica recesiva. Actas Dermo-sifiliográficas, 2015, 106, 376-382.	0.2	15
56	Effects of Indapamide on Atherosclerosis Development in Cholesterol-Fed Rabbits. Journal of Cardiovascular Pharmacology, 1995, 25, 973-978.	0.8	14
57	Growth inhibitory activity of indapamide on vascular smooth muscle cells. European Journal of Pharmacology, 2001, 428, 19-27.	1.7	13
58	Long-Term Skin Regeneration From a Gene-Targeted Human Epidermal Stem Cell Clone. Molecular Therapy, 2014, 22, 1878-1880.	3.7	13
59	IKKα regulates the stratification and differentiation of the epidermis: implications for skin cancer development. Oncotarget, 2016, 7, 76779-76792.	0.8	13
60	Applicability of bioengineered human skin: From preclinical skin humanized mouse models to clinical regenerative therapies. Bioengineered Bugs, 2011, 2, 203-207.	2.0	11
61	Human Involucrin Promoter Mediates Repression-Resistant and Compartment-Specific LEKTI Expression. Human Gene Therapy, 2012, 23, 83-90.	1.4	11
62	Pigmentation and melanocyte supply to the epidermis depend on type <scp>XVII</scp> collagen. Experimental Dermatology, 2014, 23, 130-132.	1.4	10
63	Efficient CRISPR-Cas9-Mediated Gene Ablation in Human Keratinocytes to Recapitulate Genodermatoses: Modeling of Netherton Syndrome. Molecular Therapy - Methods and Clinical Development, 2020, 18, 280-290.	1.8	10
64	The importance of immunity in the development of reliable animal models for psoriasis and atopic dermatitis. Immunology and Cell Biology, 2020, 98, 626-638.	1.0	9
65	Effects of indapamide on contractile responses and 45Ca2+ movements in various isolated blood vessels. European Journal of Pharmacology, 1993, 250, 133-139.	1.7	8
66	Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report. Frontiers in Medicine, 2020, 7, 576558.	1.2	7
67	Bioengineered Skin Humanized Model of Psoriasis. Methods in Molecular Biology, 2013, 961, 305-323.	0.4	6
68	Remote diffuse reflectance spectroscopy sensor for tissue engineering monitoring based on blind signal separation. Biomedical Optics Express, 2014, 5, 3231.	1.5	6
69	Transcriptomic Analysis of a Diabetic Skin-Humanized Mouse Model Dissects Molecular Pathways Underlying the Delayed Wound Healing Response. Genes, 2021, 12, 47.	1.0	6
70	Immunotherapeutic effect of adenovirus encoding antimicrobial peptides in experimental pulmonary tuberculosis. Journal of Leukocyte Biology, 2021, 110, 951-963.	1.5	5
71	Antiproliferative effects of PCA-4230, a new antithrombotic drug, in vascular smooth muscle cells. British Journal of Pharmacology, 1997, 120, 1360-1366.	2.7	4
72	Long‐term skin regeneration in xenografts from <scp>iPSC</scp> teratoma‐derived human keratinocytes. Experimental Dermatology, 2016, 25, 736-738.	1.4	4

#	Article	IF	Citations
73	Natural Occurrence of Autoantibodies against Basement Membrane Proteins in Epidermolysis Bullosa. Journal of Investigative Dermatology, 2022, 142, 2014-2019.e3.	0.3	4
74	Effect of somatostatin on resistance and on capacitance rabbit isolated arteries. European Journal of Pharmacology, 2000, 388, 255-261.	1.7	3
75	Recent advances in gene therapy with skin cells. European Review, 2002, 10, 369-388.	0.4	3
76	Humanization of Tumor Stroma by Tissue Engineering as a Tool to Improve Squamous Cell Carcinoma Xenograft. International Journal of Molecular Sciences, 2020, 21, 1951.	1.8	3
77	Combined adipose mesenchymal stromal cell advanced therapy resolved a recalcitrant leg ulcer in an 85-year-old patient. Regenerative Medicine, 2020, 15, 2053-2065.	0.8	2
78	FPR2 DNA Aptamers for Targeted Therapy of Wound Repair. Journal of Investigative Dermatology, 2022, 142, 2238-2248.e8.	0.3	2
79	Current Applications for Bioengineered Skin. , 2016, , 107-120.		1
80	Terapias avanzadas en enfermedades raras. Arbor, 2018, 194, 467.	0.1	1
81	EpidermÃ³lisis ampollosa distrÃ³fica recesiva y gestaciÃ³n. Progresos En Obstetricia Y Ginecologia, 2009, 52, 529-532.	0.0	0
82	Tumor initiation by skin Ha‹i›â€‹ras‹/i›â€‹ment. Experimental Dermatology, 2015, 24, 252-253.	1.4	0